Benzinga | Aug 31, 2020 08:51AM EDT

Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $179

Morgan Stanley maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $177 to $179.